Gosselies, Hainaut, Belgium, November 2025 – AbolerIS Pharma, a biotechnology company pioneering therapies to restore immune tolerance, has appointed Philippe Alen as its Chief Business Officer (CBO). With more than 25 years of global experience in business development, licensing, mergers and acquisitions, and alliance management across the biotech and pharmaceutical sectors, Philippe will lead AbolerIS Pharma’s strategic partnerships, financing activities, and corporate growth initiatives.
In his new role, Philippe will oversee business development and corporate strategy, working closely with the executive leadership team to translate AbolerIS’ immunology expertise into impactful collaborations and value-creating partnerships. His appointment strengthens AbolerIS’ leadership bench as the company advances its lead program, ABO21009, currently in Phase 1 trials for Rheumatoid Arthritis, and explores broader applications of its immune tolerance platform.
Before joining AbolerIS Pharma, Philippe Alen founded Helix BioPartners, a strategic and corporate development consultancy specializing in biopharma growth and partnerships. Through Helix, he advised emerging biotech companies on fundraising, strategic transactions, and business expansion initiatives.
Previously, Philippe served as Senior Vice President, Head of Business Development at Galapagos, where he led global partnering strategies, licensing negotiations, and alliance management. His leadership helped strengthen Galapagos’ collaboration ecosystem and expand its strategic footprint in the biotech landscape.
He also held senior leadership roles at Bayer, serving as Vice President, Business Development, Licensing, and Alliance Management, where he managed partnerships and licensing initiatives across Cardiovascular, Endocrine, and Reproductive Health divisions. His tenure at Johnson & Johnson’s Janssen Pharmaceuticals spanned 14 years, including positions such as Senior Director, Business Development and Interim Head of Business Development for Infectious Diseases and Vaccines, where he led multiple global deals from evaluation to execution.
Earlier in his career, Philippe gained extensive experience in marketing and business development roles at Virco and Phase 1 BioResearch, where he transitioned from scientific research to business leadership. His foundation as a Postdoctoral Fellow at VIB enriched his scientific acumen, which continues to underpin his strategic decision-making in business and biotech innovation.
AbolerIS Pharma is a clinical-stage biotech company focused on restoring immune tolerance while preserving protective immunity. Founded by a team with deep translational expertise in regulatory T cells and tolerance mechanisms, AbolerIS is developing novel therapeutic approaches for inflammatory, autoimmune, and degenerative diseases. The company’s lead candidate, ABO21009, is currently in Phase 1 clinical development for the treatment of Rheumatoid Arthritis.
Headquartered in Gosselies (Belgium) and Nantes (France), AbolerIS is dedicated to advancing next-generation immunotherapies that reimagine the treatment paradigm for immune-mediated disorders.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
